Daiwa Securities Group Inc. Bristol Myers Squibb CO Transaction History

Daiwa Securities Group Inc.

$21.6 Billion
Q3 2024

A detailed history of Daiwa Securities Group Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 330,191 shares of BMY stock, worth $19.1 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

330,191

Previous 251,882 31.09%

Holding current value

$19.1 Million

Previous $10.5 Million 63.31%

% of portfolio

0.08%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $3.11 Million - $4.05 Million	78,309 Added 31.09%	330,191 $17.1 Million
Q2 2024 Aug 07, 2024	BUY	$40.25 - $52.99 $1.62 Million - $2.14 Million	40,369 Added 19.09%	251,882 $10.5 Million
Q1 2024 May 02, 2024	BUY	$47.98 - $54.4 $1.01 Million - $1.14 Million	20,988 Added 11.02%	211,513 $11.5 Million
Q4 2023 Jan 31, 2024	BUY	$48.48 - $57.85 $589,516 - $703,456	12,160 Added 6.82%	190,525 $9.78 Million
Q3 2023 Nov 01, 2023	BUY	$57.89 - $64.73 $430,585 - $481,461	7,438 Added 4.35%	178,365 $10.4 Million
Q2 2023 Jul 31, 2023	BUY	$63.71 - $70.74 $123,597 - $137,235	1,940 Added 1.15%	170,927 $10.9 Million
Q1 2023 May 02, 2023	BUY	$65.71 - $74.53 $730,366 - $828,400	11,115 Added 7.04%	168,987 $11.7 Million
Q4 2022 Feb 06, 2023	BUY	$68.48 - $81.09 $720,683 - $853,391	10,524 Added 7.14%	157,872 $11.4 Million
Q3 2022 Nov 02, 2022	SELL	$0.13 - $76.84 $458 - $271,091	-3,528 Reduced 2.34%	147,348 $10.5 Million
Q2 2022 Aug 09, 2022	BUY	$72.62 - $79.98 $905,789 - $997,590	12,473 Added 9.01%	150,876 $11.6 Million
Q1 2022 Apr 29, 2022	BUY	$61.48 - $73.72 $280,410 - $336,236	4,561 Added 3.41%	138,403 $10.1 Million
Q4 2021 Feb 03, 2022	BUY	$53.63 - $62.52 $274,478 - $319,977	5,118 Added 3.98%	133,842 $8.35 Million
Q3 2021 Nov 05, 2021	SELL	$59.17 - $69.31 $320,997 - $376,006	-5,425 Reduced 4.04%	128,724 $7.62 Million
Q2 2021 Aug 06, 2021	SELL	$61.91 - $67.42 $218,913 - $238,397	-3,536 Reduced 2.57%	134,149 $8.96 Million
Q1 2021 May 03, 2021	SELL	$59.34 - $66.74 $4.49 Million - $5.05 Million	-75,661 Reduced 35.46%	137,685 $8.69 Million
Q4 2020 Feb 04, 2021	BUY	$57.74 - $65.43 $4.87 Million - $5.52 Million	84,301 Added 65.33%	213,346 $13.2 Million
Q3 2020 Nov 02, 2020	SELL	$57.43 - $63.64 $657,228 - $728,296	-11,444 Reduced 8.15%	129,045 $7.78 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $297,609 - $432,496	6,414 Added 4.78%	140,489 $7.83 Million
Q4 2019 Jan 31, 2020	BUY	$49.21 - $64.19 $3.06 Million - $4 Million	62,275 Added 86.73%	134,075 $8.61 Million
Q3 2019 Nov 04, 2019	BUY	$42.77 - $50.71 $236,560 - $280,477	5,531 Added 8.35%	71,800 $3.64 Million
Q2 2019 Jul 24, 2019	SELL	$44.62 - $49.34 $725,075 - $801,775	-16,250 Reduced 19.69%	66,269 $3.01 Million
Q1 2019 Apr 26, 2019	SELL	$45.12 - $53.8 $1.29 Million - $1.53 Million	-28,485 Reduced 25.66%	82,519 $3.94 Million
Q4 2018 Feb 05, 2019	SELL	$48.76 - $63.23 $3.1 Million - $4.02 Million	-63,530 Reduced 36.4%	111,004 $5.77 Million
Q3 2018 Nov 01, 2018	SELL	$55.19 - $62.25 $1.06 Million - $1.2 Million	-19,250 Reduced 9.93%	174,534 $10.8 Million
Q2 2018 Jul 30, 2018	SELL	$50.53 - $62.98 $216,975 - $270,436	-4,294 Reduced 2.17%	193,784 $10.7 Million
Q1 2018 May 02, 2018	BUY	$59.92 - $68.98 $2.79 Million - $3.22 Million	46,631 Added 30.79%	198,078 $12.5 Million
Q4 2017 Feb 06, 2018	SELL	$59.94 - $65.35 $2.52 Million - $2.75 Million	-42,100 Reduced 21.75%	151,447 $9.28 Million
Q3 2017 Nov 02, 2017	BUY	$55.23 - $63.74 $10.7 Million - $12.3 Million	193,547	193,547 $12.3 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.

Account

Daiwa Securities Group Inc. Bristol Myers Squibb CO Transaction History